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Abstract 
Background: Malaria is one of the most serious infectious diseases in the world. The malaria burden is greatly 
affected by human immunity, and immune responses vary between populations. Genetic diversity in KIR and HLA-C 
genes, which are important in immunity to infectious diseases, is likely to play a role in this heterogeneity. Several 
studies have shown that KIR and HLA-C genes influence the immune response to viral infections, but few studies have 
examined the role of KIR and HLA-C in malaria infection, and these have used low-resolution genotyping. The aim of 
this study was to determine whether genetic variation in KIR and their HLA-C ligands differ in Ugandan populations 
with historically varied malaria transmission intensity using more comprehensive genotyping approaches.
Methods: High throughput multiplex quantitative real-time PCR method was used to genotype KIR genetic variants 
and copy number variation and a high-throughput real-time PCR method was developed to genotype HLA-C1 and C2 
allotypes for 1344 participants, aged 6 months to 10 years, enrolled from Ugandan populations with historically high 
(Tororo District), medium (Jinja District) and low (Kanungu District) malaria transmission intensity.
Results: The prevalence of KIR3DS1, KIR2DL5, KIR2DS5, and KIR2DS1 genes was significantly lower in populations from 
Kanungu compared to Tororo (7.6 vs 13.2%: p = 0.006, 57.2 vs 66.4%: p = 0.005, 33.2 vs 46.6%: p < 0.001, and 19.7 vs 
26.7%: p = 0.014, respectively) or Jinja (7.6 vs 18.1%: p < 0.001, 57.2 vs 63.8%: p = 0.048, 33.2 vs 43.5%: p = 0.002, and 
19.7 vs 30.4%: p < 0.001, respectively). The prevalence of homozygous HLA-C2 was significantly higher in populations 
from Kanungu (31.6%) compared to Jinja (21.4%), p = 0.043, with no significant difference between Kanungu and 
Tororo (26.7%), p = 0.296.
Conclusions: The KIR3DS1, KIR2DL5, KIR2DS5 and KIR2DS1 genes may partly explain differences in transmission inten-
sity of malaria since these genes have been positively selected for in places with historically high malaria transmis-
sion intensity. The high-throughput, multiplex, real-time HLA-C genotyping PCR method developed will be useful in 
disease-association studies involving large cohorts.
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Background
Malaria is estimated to cause nearly half a million deaths 
each year worldwide [1]. Malaria is a known evolutionary 
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polymorphisms that protect against malaria. Red blood 
cell alterations are the most studied genetic abnormali-
ties that impact on malaria [2]. These include mutations 
in the alpha- and beta-globin genes that lead to sickle cell 
anaemia or thalassemias, glucose-6-phosphate dehydro-
genase (G6PD) deficiency and the Duffy antigen protein 
[3]. It has been suggested that many of these polymor-
phisms were selected in human populations due to their 
role in protection from the detrimental effects of Plasmo-
dium falciparum infection [4]. It has been demonstrated 
that different populations have developed independent 
evolutionary responses to malaria [5]. For example, 3 
haemoglobin variants (HbS, HbC, and HbE) appear to 
confer protection against malaria in different parts of the 
world [6]. The HbS allele is common in Africa, but rare in 
Southeast Asia, and the opposite is true for the HbE allele 
[7, 8].
A recent genome wide association study of 17,000 
individuals in Africa reported that known genetic vari-
ants account for only 11% of the total genetic influence 
of malaria on the human genome [9]. Among other genes 
potentially influencing malaria responses are those medi-
ating innate immunity, which is important in protection 
from P. falciparum infection. Natural killer (NK) cells 
play an important role in the innate immune response to 
malaria infection [10, 11]. NK cells are the first cells in 
peripheral blood to produce interferon gamma (IFN- γ) 
in response to P. falciparum infection [11], and they have 
also been shown to participate in adaptive immunity. 
Recent evidence indicates a role for NK cells in malaria 
infection in humans and in mouse models [10, 12]. It has 
been shown that copy number variation (CNV) in KIR 
genes influences immunity to infections [13] and plays an 
important role in NK cell education [14] through interac-
tions with their HLA class I ligands. Hence, the expres-
sion of multiple copies of KIR genes could potentially 
lead to enhanced NK cell education, thereby strengthen-
ing immunity to pathogens. This has been well studied in 
viral infections, but not in malaria.
Some studies have demonstrated that individuals may 
vary in their ability to elicit an innate immune response 
to malaria infection, with clear implications for disease 
manifestations [15]. Heterogeneity in response could 
arise from variations in KIR and their major ligands, 
HLA-C molecules, that have a direct impact on NK cell 
functions [11, 16]. The frequencies of different KIR and 
HLA-C genes vary remarkably across world populations, 
which might reflect differential selection pressures as 
well as persistence of ancestral genotypes [17]. The KIR 
and HLA loci have been suggested to be fast evolving 
and under positive selection, with pathogen pressure as 
the driving force [18, 19]. Genetic variation of KIR and 
their HLA-C ligands across the African continent is not 
well documented. Several studies have linked high KIR 
and HLA genetic diversity in Africa to malaria pressure 
[20–22]. However, there is limited data regarding the dis-
tribution of KIR and HLA variants in populations with 
varied malaria transmission intensity. Since interactions 
between the genetically diverse KIR and HLA molecules 
modulate the functionality of the NK cell response to 
malaria infections, a better understanding of the distri-
bution of KIR and HLA genes in populations with var-
ied malaria transmission intensity will be important in 
appreciating the impact of P. falciparum malaria on the 
evolution of KIR and HLA genes.
To date, there is limited data on the distribution of 
KIR and their HLA-C ligands in populations with var-
ied malaria transmission intensity. This is partly due to 
the genotyping approaches that only reveal informa-
tion about presence or absence of KIR and HLA genes. 
Furthermore, the few studies that have been carried out 
are case–control comparisons of severe versus uncom-
plicated malaria, with limited genetic information about 
KIR and HLA genes. As an alternative approach, more 
comprehensive genotyping techniques that provide addi-
tional information like copy number variation in these 
genes were used to evaluate the diversity of KIR genes 
and their HLA-C ligands in humans living in populations 
with historically varied malaria transmission intensity.
Methods
Study samples and populations
Samples from cohorts enrolled at 3 sites in Uganda 
were utilized, that is, Nagongera Sub-county in Tororo 
District, a rural area in southeastern Uganda with his-
torically high malaria transmission intensity; Walukuba 
Sub-county in Jinja District, a peri-urban area near the 
city of Jinja in south-central Uganda with historically 
moderate malaria transmission intensity; and Kihihi Sub-
county in Kanungu District, a rural area in southwest-
ern Uganda with historically low malaria transmission 
intensity.
The total population of Nagongera sub-county, Tororo 
District was 37,500. All participants at this site were 
recruited within Nagongera Health Center IV, which is 
the largest public health facility in the sub-county treat-
ing an average of 2044 patients per month. Walukuba 
sub-county, Jinja District has an estimated population of 
31,900. Study participants from Walukuba sub-county 
were recruited within Walukuba health centre IV, the 
largest public health facility in the sub-county and treat-
ing an average of 3198 patients per month. Kihihi is 
a rural sub-county in Kanungu District with an esti-
mated population of 55,700. Study participants were 
recruited within Kihihi health centre IV, which is the 
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largest healthcare facility in Kihihi sub-county, a public 
health facility that treated an average of 1945 patients per 
month.
To establish these cohorts, all households within the 
3 sites were enumerated and mapped, and randomly 
selected 100 households, that included at least one 
resident 6  months to 10  years of age, and which were 
enrolled and followed from August 2011 to September 
2013, as previously described [23]. All the participants 
enrolled in these cohorts provided thick blood smears 
and a blood sample for genetic analysis. For this study, 
all participants whose parents consented to future use of 
their samples were considered. No a priori power calcu-
lation was performed.
Sample collection and DNA purification
Blood samples from previous studies [23] were collected 
into EDTA tubes, and human genomic DNA was purified 
from buffy coats using QIAamp DNA Mini Kits (Qiagen), 
following manufacturer’s instructions using kit inserts 
with minor modifications. For each sample, 300  μl of 
buffy coat was mixed with 20 μl of kit protease enzyme 
solution and then 200 μl of lysis buffer; the mixture was 
vortexed for 15 s and incubated at 56 °C for 10 min, and 
then 200 μl of absolute ethanol was added. The mixture 
was vortexed briefly and transferred to a QIAamp col-
umn, and the column was spun for 1  min at 8000  rpm. 
The column was then washed twice with kit wash buffer, 
and DNA was eluted by incubating with 80 μl of kit elu-
tion buffer at room temperature for 5  min followed by 
centrifugation at 8000 rpm for 5 min. The DNA concen-
tration was determined using a Qubit fluorimeter (Life 
Technologies, Carlsbad, CA, USA), and the isolated DNA 
was stored at − 20 °C.
Preparation of DNA for multiplex qPCR
To prepare human genomic DNA for KIR and HLA-C 
genotyping as well as KIR copy number identification, 
10 ng samples of genomic DNA (2.5 µl of 4 ng/µl) were 
aliquoted into 384-well plates using the Hydra 96 micro 
dispenser (Art Robbins, San Jose, CA, USA) [24]. The 
DNA was air dried in the plates for subsequent multiplex 
quantitative PCR assays. Molecular grade water was used 
in all reactions.
KIR genotyping by high‑throughput, multiplex, real‑time 
qPCR
Two pairs of primers were used for each gene, as pre-
viously described [25]. Additional KIR primers were 
designed using sequence information from the immuno 
polymorphism database-KIR (IPD-KIR) database (release 
2.4.0) to detect rare alleles of KIR2DS5 and KIR2DL3 
(KIR2DS5, 2DS5rev2: TCC AGA GGG TCA CTG GGA 
and KIR2DL3, 2DL3rev3: AGA CTC TTG GTC CAT 
TAC CG) [26]. Samples were genotyped for copy num-
ber by multiplex quantitative PCR for all the KIR genes 
(KIR2DL1, 2DL2, 2DL3, 2DL4, 2DL5, 2DS1, 2DS2, 2DS3, 
2DS4, 2DS5, 2DP1, 3DP1, 3DL1, 3DL2, 3DL3, 3DS1) [24]. 
Reactions were carried out in quadruplicate to ensure 
accuracy of the copy number scoring. Two controls with 
known copy number and one non-template control were 
included in each run. Two assays for both 3DL1 and 
3DL2 genes that target different exons of the genes were 
included to identify known fusion genes [27], which are 
carried on a truncated haplotype (with 2DS4 completely 
deleted) seen in individuals of African descent. There is 
a drop in copy number for exon 9 of 3DL1 and exon 4 
of 3DL2 (i.e., discordance between the exon 4 and exon 
9 copy numbers in the same gene) when the fusion gene 
is present. Assays for 2DS4 variants, 2DS4DEL (a 22-bp 
deletion in exon 5 that causes a frameshift mutation) and 
2DS4WT (full-length gene) were also included.
HLA‑C genotyping by high‑throughput, multiplex, 
real‑time qPCR
A high-throughput real-time qPCR for genotyping HLA-
C allotypes was developed. For every reaction, KAPA 
SYBR buffer (5 µl), forward primer (1 µl), reverse primer 
(1 µl), and water (4 µl) were added to dried DNA in the 
384-well plates. HLA-C1 PCR conditions were: denatura-
tion at 95 °C for 3 min, 5 cycles of 95 °C for 3 s and 72 °C 
for 30 s, followed by 35 cycles of 95 °C for 3 s and 70 °C 
for 30  s, dissociation at 60  °C for 1  s, and finally 95  °C. 
HLA-C2 PCR conditions were: denaturation at 95 °C for 
3 min, 5 cycles of 95 °C for 3 s and 72 °C for 45 s, followed 
by 40 cycles of 95  °C for 3  s and 70  °C for 45  s, disso-
ciation at 60  °C for 1 s, and finally 95  °C. In each HLA-
C allotype, primers were used at 5  µM concentrations. 
Primer combinations for C1 and C2 were: C1 = C1Fa and 
C1Fb with C1R, and C2 = C2F with C2R, respectively 
(Table 1). This method was validated against a large range 
of samples, the HLA Reference Panel from Coriell with 
known HLA-C allotypes, and in families. The sequences 
for each of the primers used are shown in Table 1.
Table 1 HLA-C primers for high-throughput qPCR
Primer name Sequence
C1Fa GCC GCG AGT CCA AGAGG 
C1Fb GCC GCG AGT CCG AGAGG 
C2F CTG ACC GAG TGA ACC TGC GGAAA 
C2R GGA GAT GGG GAA GGC TCC CCAC 
C1R GCG CAG GTT CCG CAGGC 
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KIR and HLA‑C genotypes analysis
KIR genotypes were defined following the recommen-
dations from the 2011 KIR workshop that was held at 
Tammsvik, Stockholm, Sweden [28]. Briefly, the centro-
meric A region (cenA) was defined by the presence of 
KIR2DL3 and KIR2DL1 and absence of any A haplotype 
gene; the centromeric B (cenB) region was defined by 
presence of any centromeric B haplotype gene (KIR2DS2 
and/or KIR2DL2, and/or 2DL5B and/or centromeric 
2DS3/5). The telomeric A (telA) region was defined by 
KIR3DL1 and KIR2DS4 and absence of any A haplotype 
gene, and the telomeric B (telB) region was defined by 
presence of any centromeric B haplotype gene (KIR3DS1 
and/or KIR2DS1 and or 2DL5B and/or telomeric 2DS5) 
(Fig. 1). The KIR and HLA-C genotypes were ascertained 
according to the Allele Frequency Net Database (http://
www.allel e.frequ encie s.net).
KIR Copy number determination by multiplex quantitative 
PCR
Copy numbers for all KIR genes (KIR2DL1–5, 2DS1–5, 
2DS4 (separate assays for the gene, wild-type variant 
[2DS4WT], and deletion variant [2DS4DEL]), 2DP1, 
3DP1, 3DL1-3 and 3DS1) were determined using a Roche 
Light Cycler 480. Copy numbers were measured by rela-
tive quantification analysis of the target KIR gene and 
reference gene (signal transducer and activator of tran-
scription 6; STAT 6) using the comparative Cq method 
[24, 29]. Cq value is the qPCR cycle at which fluores-
cence from amplification exceeds the background fluo-
rescence (also referred to as threshold cycle, Ct). The 
ΔΔCq was used to calculate KIR copy number. The first 
ΔCq was calculated by the cycle threshold difference 
between the target and reference assay of the same sam-
ple. The second ΔCq was calculated by the difference of 
ΔCq values from a test sample and a calibrator sample 
with known copy number of the target. Two controls 
with known copy number and one non-template control 
were included in each run. COPYCALLER software from 
Applied Biosystems (Foster City, CA, USA) was used to 
score KIR copy numbers. When the Cq of the reference 
gene was greater than 32 or a data point was more than 
4 SD from the mean ΔCq of four replicates, the reaction 
was not analysed. KIR copy number frequencies were cal-
culated for all the samples.
Statistical methods
Data across the 3 sites was described using frequencies 
and percentages for categorical variables. Frequencies of 
KIR genes, KIR genotypes and HLA-C allotypes were cal-
culated by direct counting. Differences in the distribution 
of KIR and HLA-C genetic variants within the three pop-
ulations were compared by Chi-square and Mid-P exact 
tests. A p-value < 0.05 was considered significant.
Results
Characteristics of study participants and populations
Among the 1,344 subjects in the 3 cohorts, 44% were 
under 5 years of age, and 56% between 5 and 10 years. A 
recent report defined malaria transmission, prevalence, 
and incidence in the 3 cohorts (Table 2) [23]. The 3 sites 
differed markedly, with very high transmission intensity, 
parasite prevalence and malaria incidence in Tororo Dis-
trict, lower levels of all of these parameters in Kanungu 
Fig. 1 KIR haplotypes. KIR A haplotypes (a, b) are present in all populations worldwide. KIR A haplotype is composed of mainly inhibitory KIR except 
KIR2DS4. Allelic polymorphism is very high in the KIR A haplotype (KIR3DL1, 3DL2 and 3DL3 exhibit > 100 alleles, and 2DL1 and 2DL3 exhibit ~ 50 
alleles). Haplotypes (b) has several activating receptors, with variable number of genes and fewer allelic polymorphisms. Some KIR B haplotypes are 
composed of combinations of haplotypes (a, b) (CenA-TelB, CenB-TelA). The HLA epitopes bound by some KIRs are known and are indicated as C1, 
C2 or Bw4
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District, and the lowest levels in Jinja District [23, 30]. 
Of note, malaria transmission was considerably greater 
in earlier surveys in Jinja District [31], with decreasing 
transmission likely due to the peri-urban nature of the 
study area. In Tororo District, transmission has subse-
quently decreased greatly, after annual indoor residual 
spraying of insecticides was launched in 2014 [32]. His-
torically, malaria transmission intensity followed the rank 
order Tororo > Jinja > Kanungu [31]. The aim of this study 
was to compare KIR and HLA-C genetic variants that 
may have been selected due to differential malaria selec-
tion pressures at these sites.
Comparative prevalence of KIR and HLA‑C genetic variants 
at 3 sites in Uganda
Analysis for differential prevalence of KIR genes, KIR 
genotypes, HLA-C allotypes (HLA-C1C1, C1C2, C2C2), 
centromeric and telomeric KIR motifs and KIR/HLA-C 
combinations across the 3 populations was carried out 
(Table  3). More than 90% of samples from all the study 
populations were successfully analysed for KIR and 
HLA-C genetic variants. The prevalence of the inhibi-
tory KIR genes KIR2DL1 and KIR3DL1 and the activat-
ing gene KIR2DS4 was very high (> 95%). The prevalence 
of KIR3DS1 was generally low across the 3 populations, 
with the lowest prevalence in Kanungu (7.6%) compared 
to Jinja (18.1%) and Tororo (13.2%). The prevalence 
of KIR2DS5 was lower in Kanungu (33.2%) compared 
to Jinja (43.5%) and Tororo (46.6%). The prevalence of 
HLA-C1C2 heterozygotes was higher (53.4%) in all 3 
populations compared to homozygous HLA-C1 (20.1%) 
or homozygous HLA-C2 (26.5%).
The prevalence of KIR3DS1, 2DL5, 2DS5, and 2DS1 
genes was significantly lower in Kanungu compared 
to both Tororo (7.6 vs 13.2%: p = 0.006, 57.2 vs 66.4%: 
p = 0.005, 33.2 vs 46.6%: p < 0.001, and 19.7% vs 26.7%: 
p = 0.014, respectively) and Jinja (7.6 vs 18.1%: p < 0.001, 
57.2 vs 63.8%: p = 0.048, 33.2 vs 43.5%: p = 0.002 and 19.7 
vs 30.4%: p < 0.001, respectively). There was no signifi-
cant difference in the prevalence of inhibitory KIR2DL1, 
2DL2, 2DL3, and 3DL1 and activating KIR2DS2, 2DS3 
and 2DS4 (Table  4). The prevalence of homozygous 
HLA-C2 was significantly higher in Kanungu (31.6%) 
compared to Jinja (21.4%), p = 0.043. No significant dif-
ference was observed between the prevalence of HLA-C2 
in Tororo (26.7%) and Kanungu (31.6%), p = 0.296. There 
was no significant difference in the prevalence of KIR AA 
and KIR BX genotypes in Tororo and Jinja (p = 0.145), 
Tororo and Kanungu (p = 0.877), or Jinja and Kanungu 
(p = 0.098). Combinations of KIR genotypes with HLA-C 
ligands did not differ in the 3 populations. There was no 
significant difference in the KIR centromeric or telomeric 
motifs across the 3 populations (Table 5).
Copy number variation in KIR genes and malaria 
transmission intensity
Determination of whether CNV in KIR genes is influ-
enced by malaria transmission intensity was done by 
comparing KIR CNV in children from the 3 populations. 
Comparisons were done for inhibitory KIR2DL1, 2DL2, 
2DL3, and 2DL5, and the activating KIR2DS2 and 2DS5. 
All the KIR genes, including framework genes, were sub-
ject to CNV. The majority of study participants (over 
90%) had 0–2 copies. However, there was no significant 
difference in KIR CNV across the 3 study populations 
(Table 6), suggesting that CNV in KIR genes may not be 
influenced by P. falciparum pathogen pressure.
Discussion
Most studies about genetic variation in KIR and HLA 
class I molecules and malaria have focused mainly on 
protection from severe malaria [33]. The aim of this 
study was to determine whether KIR and HLA-C genetic 
variants and CNV in KIR genes from 3 populations of 
Uganda with historically varied malaria transmission 
intensity have been shaped by selection pressure from 
falciparum malaria. Appreciation of malaria transmission 
prior to recent intensive control efforts and urbanization 
suggests a rank order for historical transmission inten-
sity of Tororo > Jinja > Kanungu [31]. Thus, the measured 
prevalence of KIR genes and their HLA-C ligands in pop-
ulations with historically varied malaria transmission was 
Table 2 Characteristics of  study participants 
and populations




 Location South-eastern South-central South-western
 Setting Rural Peri-urban Rural
 Altitude 695–1443 m 1102–1500 m 886–1329 m
Number of study subjects
 Children below 5 years 340 321 365
 Children 5–10 years 106 114 98
 Total 446 435 463
Malaria indicators (children)a
 Entomological inocula-
tion rate per year
310 2.8 32.0
 Parasite prevalence 28.7% 7.4% 9.3%
 Malaria incidence per 
year
2.81 0.43 1.43
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Table 3 Distribution of KIR and HLA-C genetic variants at the 3 sites in Uganda
Genetic variants Study sites
Tororo, N = 438 n (%) Jinja, N = 414 n (%) Kanungu, 
N = 446 n 
(%)
KIR genes
 2DS2 224 (51.1) 218 (52.7) 228 (51.1)
 2DL2 254 (58.0) 240 (58.0) 254 (57.0)
 2DL3 366 (83.6) 352 (85.0) 380 (85.2)
 2DP1 432 (98.6) 409 (98.8) 442 (99.1)
 2DL1 432 (98.6) 409 (98.8) 441 (98.9)
 3DL1 421 (96.1) 394 (95.2) 439 (98.4)
 3DS1 58 (13.2) 75 (18.1) 34 (7.6)
 2DL5 291 (66.4) 264 (63.8) 255 (57.2)
 2DS5 204 (46.6) 180 (43.5) 148 (33.2)
 2DS3 92 (21.0) 84 (20.3) 111 (24.9)
 2DS1 117 (26.7) 126 (30.4) 88 (19.7)
 2DS4 424 (96.8) 392 (94.7) 438 (98.2)
Tororo, N = 385 n (%) Jinja, N = 392 n (%) Kanungu, 
N = 433 n 
(%)
KIR genotypes
 AA 150 (39.0) 133 (33.9) 171 (39.5)
 BX 235 (61.0) 259 (66.1) 262 (60.5)
Tororo, N = 356 n (%) Jinja, N = 168 n (%) Kanungu, 
N = 405 n 
(%)
HLA-C allotypes
 C1C1 66 (18.5) 39 (23.2) 75 (18.5)
 C1C2 195 (54.8) 93 (55.4) 202 (49.9)
 C2C2 95 (26.7) 36 (21.4) 128 (31.6)
Tororo, N = 438 n (%) Jinja, N = 414 n (%) Kanungu, 
N = 446 n 
(%)
Centromeric KIR region
 CenAA 191 (43.6) 171 (41.3) 190 (42.6)
 CenAB 175 (40.0) 182 (44.0) 192 (43.1)
 CenBB 72 (16.4) 61 (14.7) 64 (14.3)
Tororo, N = 438 n (%) Jinja, N = 413 n (%) Kanungu, 
N = 446 n 
(%)
Telomeric KIR region
 TelAA 314 (71.7) 283 (68.5) 356 (79.8)
 TelAB 115 (26.3) 112 (27.1) 83 (18.6)
 TelBB 9 (2.0) 18 (4.4) 7 (1.6)
Tororo, N = 313 n (%) Jinja, N = 152 n (%) Kanungu, 
N = 393 n 
(%)
Combinations of KIR haplotypes/HLA-C
 AA/C1C1 21 (6.7) 11 (7.3) 22 (5.6)
 AA/C1C2 62 (19.8) 37 (24.3) 93 (23.7)
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aimed at understanding impacts of malaria evolutionary 
pressure on KIR and HLA genes.
There was high KIR diversity in the 3 studied popu-
lations, as has been seen in previous studies in Uganda 
[20] and in other African populations [34]. Generally, the 
frequency of KIR3DS1 was low across the 3 populations, 
similar to that reported in previous studies from other 
African populations [35]. The frequency of KIR3DS1 
was significantly lower in Kanungu compared to Tororo 
and Jinja, implying that KIR3DS1 could have been posi-
tively selected for in Tororo and Jinja to offer some 
advantage against malaria. The prevalence of KIR2DS5 
and KIR2DL5 genes was significantly lower in Kanungu. 
Interestingly, results from a previous study in Nigeria 
demonstrated that KIR2DS5 and KIR2DL5 genes were 
associated with reduced parasitaemia [36]. The KIR3DS1, 
KIR2DL5, KIR2DS5 and KIR2DS1 genes can be present 
together on a particular haplotype in sub-Saharan Afri-
cans [37]. Differences in the prevalence of this haplo-
type across the three sites could potentially be explained 
by the selective pressure imposed by malaria. If so, 
the responsible gene or genes on the haplotype are not 
known, but KIR3DS1 has a low frequency and is present 
on few other haplotypes in Ugandans [38]. This gene is 
more prevalent in other populations, including Europe-
ans [39], suggesting that it is selected against in Uganda 
or it evolved outside Africa [35]. The observed differences 
may be due, in part, to genetic differences between the 
ethnic groups principally inhabiting these populations. 
Indeed, in the previous study from these cohorts, it was 
observed that the populations of Tororo and Kanungu 
were homogeneous, based on language groups, but the 
Jinja population had ethnic groups from all over Uganda 
[40]. Although the specific ligands and expression details 
for KIR2DS3 and KIR2DS5 are yet to be defined, it is 
speculated that under functionally relevant combinations 
these activating genes, in conjunction with their putative 
ligands, may increase the threshold of NK cell activation 
and subsequent recruitment of other immune factors 
that mediate protection against malaria.
Although there was no significant difference in KIR/
HLA-C combinations across the three sites in Uganda, it 
Table 3 (continued)
Tororo, N = 313 n (%) Jinja, N = 152 n (%) Kanungu, 
N = 393 n 
(%)
 AA/C2C2 37 (11.8) 11 (7.2) 46 (11.7)
 BX/C1C1 36 (11.5) 23 (15.1) 50 (12.7)
 BX/C1C2 109 (34.8) 46 (30.3) 105 (26.7)
 BX/C2C2 48 (15.4) 24 (15.8) 77 (19.6)
Table 4 Comparative prevalence of  KIR genes from  3 sites of  Uganda with  historically varied malaria transmission 
intensity
Mid-P exact p-values for comparisons of KIR genes in Tororo vs Jinja, Tororo vs Kanungu and Jinja vs Kanungu
Study sites
Genes Tororo, N = 438 Jinja, N = 414 Kanungu, N = 446 Mid‑P p‑values
n % n % n % T vs J T vs K J vs K
2DS2 224 51.1% 218 52.7% 228 51.1% 0.658 0.995 0.652
2DL2 254 58.0% 240 58..0% 254 57.0% 0.995 0.754 0.762
2DL3 366 83.6% 352 85.0% 380 85.2% 0.558 0.502 0.942
2DP1 432 98.6% 409 98.8% 442 99.1% 0.834 0.506 0.654
2DL1 432 98.6% 409 98.8% 441 98.9% 0.834 0.739 0.906
3DL1 421 96.1% 394 95.2% 439 98.4% 0.497 0.064 0.061
3DS1 58 13.2% 75 18.1% 34 7.6% 0.052 0.006  < 0.001
2DL5 291 66.4% 264 63.8% 255 57.2% 0.414 0.005 0.048
2DS5 204 46.6% 180 43.5% 148 33.2% 0.364  < 0.001 0.002
2DS3 92 21.0% 84 20.3% 111 24.9% 0.797 0.170 0.108
2DS1 117 26.7% 126 30.4% 88 19.7% 0.229 0.014  < 0.001
2DS4 424 96.8% 392 94.7% 438 98.2% 0.125 0.181 0.059
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should be noted that, interactions between KIR and their 
HLA-C ligands within an individual play a key role in 
modulating the activity of NK cells [41]. For instance, the 
presence of particular HLA-C allotypes and inhibitory 
KIR2DL1, KIR2DL2 and KIR2DL3 genes determines the 
strength of NK cell inhibition during malaria infection 
[33]. The best characterized KIR-HLA ligand interactions 
are KIR2DL1 with the HLA-C2 subgroup and KIR2DL2/
Table 5 Comparative prevalence of KIR and HLA-C genetic variants from 3 sites of Uganda with historically varied malaria 
transmission intensity
p-values for comparisons of the prevalence of KIR AA vs BX genotypes, HLA (C1C1) vs C1C2 vs C2C2, KIR/HLA (AA/C1C1) vs AA/C1C2 vs AA/C2C2, KIR/HLA (BX/C1C1) 
vs BX/C1C2 vs BX/C2C2, centromeric (CenAA) vs CenAB vs CenBB, telomeric (TelAA) vs TelAB vs TelBB in Tororo (T), Jinja (J) and Kanungu (K) districts were determined 
using Fisher’s exact test.
Study sites
Tororo, N = 385 Jinja, N = 392 Kanungu, N = 433 p‑values
n (%) n (%) n (%) T vs J T vs K J vs K
KIR genotypes
 AA 150 39.0% 133 33.9% 171 39.5% 0.145 0.877 0.098
 BX 235 61.0% 259 66.1% 262 60.5%
Tororo, N = 356 Jinja, N = 168 Kanungu, N = 405 p‑values
n (%) n (%) n (%) T vs J T vs K J vs K
HLA-C
 C1C1 66 18.5% 39 23.2% 75 18.5% 0.285 0.296 0.043
 C1C2 195 54.8% 93 55.4% 202 49.9%
 C2C2 95 26.7% 36 21.4% 128 31.6%
Tororo, N = 120 Jinja, N = 59 Kanungu, N = 161 p‑values
n (%) n (%) n (%) T vs J T vs K J vs K
KIRAA/HLA-C
 AA/C1C1 21 17.5% 11 18.6% 22 13.7% 0.213 0.537 0.282
 AA/C1C2 62 51.7% 37 62.8% 93 57.8%
 AA/C2C2 37 30.8% 11 18.6% 46 28.5%
Tororo, N = 193 Jinja, N = 93 Kanungu, N = 232 p‑values
n (%) n (%) n (%) T vs J T vs K J vs K
KIRBX/HLA-C
 BX/C1C1 36 18.6% 23 24.7% 50 21.5% 0.424 0.062 0.424
 BX/C1C2 109 56.5% 46 49.5% 105 45.3%
 BX/C2C2 48 24.9% 24 25.8% 77 33.2%
Tororo, N = 438 Jinja, N = 414 Kanungu, N = 446 p‑values
n (%) n (%) n (%) T vs J T vs K J vs K
Centromeric KIR motif
 CenAA 191 43.6% 171 41.3% 190 42.6% 0.478 0.552 0.928
 CenAB 175 40.0% 182 44.0% 192 43.0%
 CenBB 72 16.4% 61 14.7% 64 14.4%
Tororo, N = 438 Jinja, N = 413 Kanungu, N = 446 p‑values
n (%) n (%) n (%) T vs J T vs K J vs K
Telomeric KIR Motif
 TelAA 314 71.7% 283 68.5% 326 73.1% 0.141 0.088 0.061
 TelAB 115 26.3% 112 27.1% 113 25.3%
 TelBB 9 2.0% 18 4.4% 7 1.6%
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L3 with the HLA-C1 subgroup. Generally, KIR2DL1/
HLA-C2 provides the strongest inhibition, followed by 
KIR2DL2/HLAC1, and KIR2DL3/HLA-C1 [42, 43]. HLA-
C1/C1 individuals are only able to receive inhibitory sig-
nals via KIR2DL2 and KIR2DL3, whereas HLA-C2/C2 
individuals receive inhibitory signals predominantly via 
KIR2DL1, and heterozygous individuals have the ligand 
for all three of these KIR genes [44]. Lower KIR inhibi-
tion may allow unrestrained NK cell activation that could 
contribute to immune-mediated pathology. This would 
be consistent with the theory that mechanisms that pre-
vent malaria infection and those that prevent severe dis-
ease are distinct and may have a balancing effect on the 
maintenance of different KIR and their HLA ligands in 
malaria-endemic populations.
The role of KIR/HLA compound genotypes during 
falciparum malaria requires more attention given that 
malaria parasites spend most of the life cycle outside of 
HLA-expressing cells. Sporozoites infect hepatocytes 
after injection by mosquitoes. This is the only stage 
in the parasite replicative life cycle which is within an 
HLA-expressing host cell (39). Because erythrocyte 
membranes contain little to no HLA (42), it is postu-
lated that the influence of KIR on cell-mediated anti-
parasite immunity may occur primarily during the liver 
stage. This implies that cellular immune responses play 
an important role in restricting P. falciparum infection. 
During the blood stage, KIR-expressing effector cells may 
respond more strongly to an HLA-devoid cell due to the 
loss of inhibitory signalling via inhibitory KIR (43). KIR 
inhibition may also influence the clearance of parasites 
through antibody-dependent cellular cytotoxity (44, 45).
Previous studies have indicated that variation in KIR 
copy number, which leads to expression differences [14], 
may be important for susceptibility to some diseases. For 
example, CNV of KIR3DL1/S1 influences HIV control 
[45] and expression differences of KIR2DL3, interacting 
with HLA-C, may have a profound effect on resolution 
of hepatitis C virus infection [46]. However, there was no 
significant difference between KIR CNV across the three 
populations of Uganda.
Although different KIR and HLA variants may have 
been selected in different populations primarily due to 
differential risk of malaria, the role of other infectious 
Table 6 Comparison of CNV in KIR genes in populations with historically varied malaria transmission intensity
CNV is copy number variation of KIR genes. The value can be 0, 1 or 2 in these populations, F is the frequency of participants with the different copies of KIR genes
Tororo Jinja Kanungu p‑value
N = 438 F (%) N = 414 F (%) N = 446 F (%)
KIR2DL1 CNV
 0 6 1.4 5 1.2 5 1.2 0.985
 1 104 23.7 99 23.9 101 22.6
 2 328 74.9 310 74.9 340 76.2
KIR2DL2 CNV
 0 184 42 174 42 192 43.1 0.834
 1 220 50.2 199 48.1 216 48.4
 2 34 7.8 41 9.9 38 8.5
KIR2DL3 CNV
 0 72 16.4 62 15 66 14.8 0.195
 1 154 35.2 171 41.3 191 42.8
 2 212 48.4 181 43.7 189 42.4
KIR2DS2 CNV
 0 214 48.8 196 47.3 218 48.9 0.387
 1 207 47.3 189 45.7 204 45.7
 2 17 3.9 29 7 24 5.4
KIR2DS5 CNV
 0 336 76.7 324 78.3 372 83.4 0.144
 1 98 22.3 86 20.7 71 16
 2 4 1 4 1 3 0.6
KIR2DL5 CNV
 0 292 66.8 282 68.2 318 71.4 0.650
 1 138 31.4 126 30.5 121 27
 2 8 1.8 6 1.3 7 1.6
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pathogens that are prevalent in these malaria-endemic 
populations should not be overlooked, as they may also 
have exerted selective pressure on the evolution of KIR 
and HLA. Therefore, the role of other co-infections 
should be considered in future studies involving KIR and 
malaria, especially in populations affected by many infec-
tious pathogens.
This study had some limitations. First, the genotyp-
ing technique for both KIR and HLA-C could not give 
detailed information up to the allele level. Second, other 
HLA class I genes, for instance HLA-B (e.g., HLA Bw4 
and HLA Bw6 allotypes), which may play a role in malaria 
risk were not looked at. Nevertheless, analysis for HLA-
C allotypes, which are the major ligands for KIR genes, 
was done. Third, the status of KIR genes and their HLA-C 
ligands remain unknown in a larger part of Uganda that 
was not covered in this study given its limited cover-
age. Despite these limitations, description of the genetic 
diversity of KIR and their HLA-C ligands in populations 
with historically varied malaria transmission inten-
sity offered an opportunity to identify KIR and HLA-C 
genetic variants that are under positive selection and are 
potentially important in protection against malaria.
Conclusions
This study has provided baseline information about dif-
ferences in the prevalence KIR genes and their HLA-C 
ligands in populations of Uganda with historically varied 
malaria transmission intensity. The KIR3DS1, KIR2DL5, 
KIR2DS5, and KIR2DS1 genes may partly explain dif-
ferences in transmission intensity of malaria since these 
genes have been positively selected for in places with his-
torically high malaria transmission intensity. This is the 
largest cohort ever studied investigating KIR, HLA-C and 
malaria risk. A new high-throughput real-time PCR assay 
for HLA-C genotyping has been developed from this 
study. This will be useful in disease association studies 
that involve larger cohorts.
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